Pharmacotherapy for Pain in a Family With Inherited Erythromelalgia Guided by Genomic Analysis and Functional...

Area of Science:

• Neuroscience
• Pharmacology
• Genetics

Background:

• Inherited erythromelalgia (IEM) is characterized by hyperexcitable dorsal root ganglion (DRG) neurons due to gain-of-function mutations in the sodium channel NaV1.7.
• Effective pharmacotherapy for chronic pain, particularly IEM, remains a significant clinical challenge.

Observation:

• A study investigated the efficacy of carbamazepine in two patients with IEM harboring the NaV1.7 S241T mutation.
• Pain levels, brain activity patterns, and DRG neuron firing were assessed using behavioral measures, fMRI, and multielectrode array technology.

Findings:

• Carbamazepine significantly reduced pain intensity, duration, and frequency of pain episodes in both patients, aligning with predictions from molecular modeling and functional profiling.
• fMRI revealed a shift in brain activity from pain-processing areas to sensory and attention networks during carbamazepine treatment.
• Carbamazepine demonstrably reduced the firing of DRG neurons expressing the S241T NaV1.7 mutant channel.

Implications:

• Pharmacotherapy guided by genomic analysis and functional profiling can effectively manage neuropathic pain in patients with the NaV1.7 S241T mutation.
• This approach holds promise for developing personalized treatments for rare genetic pain disorders.
• The findings highlight the potential of targeting specific ion channel mutations for pain relief.